Arcutis Biotherapeutics Announces Stay in Ongoing Patent Litigation with Padagis
Westlake Village, CA – Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a leading biopharmaceutical company specializing in the development of innovative treatments for immune-dermatological conditions, recently made an important announcement regarding the patent litigation ongoing between Arcutis and Padagis. According to a press release dated April 2, 2025, Padagis Israel Pharmaceuticals Ltd., Padagis US LLC, and Padagis LLC (collectively, Padagis) have requested a stay in the litigation, and Arcutis has agreed to enter a joint stipulation to grant the stay.
Background of the Litigation
The patent litigation between Arcutis and Padagis began when Arcutis filed a complaint against Padagis in the U.S. District Court for the District of Delaware, alleging that Padagis had infringed upon several of Arcutis’ patents related to its psoriasis treatment, CR845. Arcutis sought injunctive relief and damages, claiming that Padagis’ actions constituted unfair competition and patent infringement.
The Stay Agreement
With the recent announcement, all scheduled dates and the trial for the patent litigation will be vacated once the Court enters the joint stipulation. The exact reasons for the stay request and the terms of the agreement have not been disclosed in the press release. However, Arcutis stated that it will continue to vigorously enforce its intellectual property rights.
Impact on Arcutis
The stay in the patent litigation may provide Arcutis with some relief as it allows the company to focus on its core business activities without the distraction and potential financial burden of an ongoing legal battle. Arcutis has been working on expanding its product portfolio and growing its commercial presence, and the stay could help the company allocate resources more efficiently towards these efforts.
Impact on the World
The patent litigation between Arcutis and Padagis is significant because it involves the intellectual property rights to a promising psoriasis treatment. CR845, Arcutis’ lead product candidate, is a topical treatment that has shown positive results in clinical trials for plaque psoriasis, a chronic autoimmune disease that affects millions of people worldwide. A resolution of the patent dispute could pave the way for greater access to effective treatments for psoriasis patients.
Conclusion
The stay in the patent litigation between Arcutis and Padagis marks a temporary resolution in a legal dispute that has the potential to impact the development and availability of innovative treatments for immune-dermatological conditions. While the reasons for the stay and the terms of the agreement have not been disclosed, the announcement provides some relief for Arcutis as it allows the company to focus on its business activities without the distraction of an ongoing legal battle. The eventual resolution of the patent dispute could lead to greater access to effective treatments for patients suffering from psoriasis and other immune-dermatological conditions.
- Arcutis Biotherapeutics and Padagis have requested a stay in the ongoing patent litigation related to Arcutis’ psoriasis treatment, CR845.
- The Court will enter a joint stipulation to grant the stay, vacating all scheduled dates and the trial for the litigation.
- The stay may provide relief for Arcutis, allowing the company to focus on its business activities without the distraction and potential financial burden of an ongoing legal battle.
- The eventual resolution of the patent dispute could lead to greater access to effective treatments for patients suffering from psoriasis and other immune-dermatological conditions.
